✦ LIBER ✦

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

✍ Scribed by Michele Kohli, Donna Lawrence, Jennifer Haig, Andrea Anonychuk, Nadia Demarteau

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immunogenicity and Safety of Human Papil

✍ M. Lehtinen; T. Petäjä; H. Keränen; T. Karppa; A. Kawa; S. Lantela; H. Levänen; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Immunogenicity and Safety of Human Papil

✍ Tiina Petäjä; Heli Keränen; Tiina Karppa; Anna Kawa; Sirkku Lantela; Mari Siitar 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 414 KB

Efficacy of the human papillomavirus (HP

✍ A. Szarewski; W.A.J. Poppe; S.R. Skinner; C.M. Wheeler; J. Paavonen; P. Naud; J. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 857 KB

Immunogenicity and safety of human papil

✍ Neerja Bhatla; Vanita Suri; Partha Basu; Surendra Shastri; Sanjoy K. Datta; Dan 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 977 KB

Quadrivalent Human Papillomavirus (HPV)

✍ Karly P. Garnock-Jones, Anna R. Giuliano 📂 Article 📅 2012 🏛 Adis International Limited (now part of Wolters Kl 🌐 English ⚖ 148 KB

Impact of malaria and helminth infection

✍ Brown, Joelle; Baisley, Kathy; Kavishe, Bazil; Changalucha, John; Andreasen, Aur 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 487 KB